TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

55.37 +2.03 (+3.81%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment ↗

March 16, 2026

Viking Therapeutics develops clinical-stage therapies for metabolic and endocrine disorders, aiming to address unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech With a Breakout MS Drug Draws $8 Million Investment Amid 30% Stock Drop ↗

March 16, 2026

This biopharma firm develops therapies for B-cell malignancies and autoimmune diseases, with a focus on oncology and immunology.

Via The Motley Fool

TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup ↗

March 14, 2026

Via Chartmill

TG Therapeutics (TGTX) Q4 2025 Earnings Transcript ↗

February 26, 2026

TG Therapeutics (TGTX) Q4 2025 Earnings Transcript

Via The Motley Fool

TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook ↗

February 26, 2026

Via Chartmill

Topics Earnings

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally ↗

January 15, 2026

Via Stocktwits

Soleus Adds a Significant Number of Celcuity Shares ↗

February 13, 2026

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win' ↗

February 09, 2026

TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.

Via Stocktwits

Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares ↗

February 02, 2026

This commercial-stage biotech develops therapies for B-cell malignancies and autoimmune diseases, leveraging a diverse clinical pipeline.

Via The Motley Fool

Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? ↗

January 14, 2026

On Tuesday, the company provided the revenue outlook for 2026 and fourth-quarter (Q4) and fiscal year 2025 revenue projection for BRIUMVI.

Via Stocktwits

Topics Artificial Intelligence

TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug ↗

November 03, 2025

Via Stocktwits

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Earnings Preview For TG Therapeutics ↗

October 31, 2025

Via Benzinga

TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 ↗

January 13, 2026

The company expects total revenue for full year 2025 to be about $616 million, including $594 million from sales of its Briumvi in the U.S.

Via Stocktwits

Topics Artificial Intelligence

These stocks are moving in today's after hours session ↗

January 13, 2026

Via Chartmill

TG Therapeutics TGTX Q3 2025 Earnings Transcript ↗

November 27, 2025

TG Therapeutics TGTX Q3 2025 Earnings Transcript

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 11, 2025

Via Benzinga

TG Therapeutics Board Authorizes New $100M Share Repurchase Program ↗

September 03, 2025

Via Stocktwits

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.

Via Investor's Business Daily

Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million ↗

November 03, 2025

Hussman Sells Off All 21,000 CHKP Shares Valued At $4.65 Million

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

Highly Watched TG Therapeutics Smashes Profit Views — With A Caveat ↗

November 03, 2025

TG Therapeutics stock rose early Monday on better-than-expected earnings.

Via Investor's Business Daily

Topics Earnings

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗

November 03, 2025

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Via Benzinga

TG THERAPEUTICS INC (NASDAQ:TGTX) Shows High Growth Momentum and Technical Breakout Setup ↗

October 07, 2025

TG Therapeutics (TGTX) shows explosive EPS growth up to 1,300% and strong sales momentum. With a perfect 10 technical rating and a bullish chart setup, it's a high-growth stock to watch.

Via Chartmill

10 Health Care Stocks Whale Activity In Today's Session ↗

October 01, 2025

Via Benzinga

TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback ↗

September 03, 2025

TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing confidence in Briumvi and growth prospects.

Via Benzinga

TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug ↗

August 04, 2025

The company raised its Briumvi U.S. net product revenue target to $570 million to $575 million for the full year 2025, up from its previous guidance of $560 million.

Via Stocktwits

Topics Earnings

Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results ↗

August 04, 2025

Via Benzinga

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide ↗

August 04, 2025

TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global growth.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.